J-curve can be defined as an increase in event rates when the blood pressure (BP) goes below a particular level. Now that we have safe and powerful drugs available for treatment of hypertension, it has become possible to bring down the BP to very low levels. However, the concept of “lower is better” is now being questioned. Trials looking at J-curve have given conflicting results. Probably, there is no J-curve for systolic BP. J-curve for stroke and renal end points is also debatable. It is in patients with significant obstructive coronary artery disease that there are data for a J curve for diastolic BP. In such patients, we should gradually titrate the dose of drugs, carefully watching for increasing angina. Isolated systolic hypertension (ISH) is another situation wherein care has to be taken when aggressively reducing systolic BP. Even here, there are questions to be answered. The low diastolic BP could be a marker of increased aortic stiffness. Or, the low diastolic BP may be due to other associated comorbid conditions. The fear of J-curve should not lead to undertreatment and thus deny patients the benefit of BP reduction.
Read full abstract